- Home
- ANAB vs QNT Comparison
ANAB vs QNT Comparison
Compare ANAB & QNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ANAB | QNT |
|---|---|---|
| Founded | 2005 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.4B |
| IPO Year | 2015 | 2026 |
Fundamental Metrics
Financial Performance| Metric | ANAB | QNT |
|---|---|---|
| Price | $48.44 | $36.58 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 13 |
| Target Price | $87.25 | ★ $95.83 |
| AVG Volume (30 Days) | 510.1K | ★ 2.0M |
| Earning Date | 11-03-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 91.02 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $234,603,000.00 | N/A |
| Revenue This Year | $17.97 | N/A |
| Revenue Next Year | $36.88 | $102.03 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 157.01 | N/A |
| 52 Week Low | $30.27 | $33.02 |
| 52 Week High | $73.30 | $86.79 |
Technical Indicators
Market Signals| Indicator | ANAB | QNT |
|---|---|---|
| Relative Strength Index (RSI) | 48.05 | 36.21 |
| Support Level | $44.43 | $33.02 |
| Resistance Level | $51.27 | $53.25 |
| Average True Range (ATR) | 2.29 | 2.55 |
| MACD | 0.44 | -0.04 |
| Stochastic Oscillator | 58.84 | 25.45 |
Price Performance
Historical ComparisonAbout ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
About QNT Quantinuum Inc. Class A Common Stock
Quantinuum Inc. is providing a full-stack quantum technology solution to scale quantum computing and develop applications. Its products and solutions are Quantinuum Systems, Helios, Quantum Origin, InQuanto, Nexus, and Developer Tools.